✦ LIBER ✦

534 Ixabepilone, a novel tubulin interacting agent, given every other week in combination with irinotecan in patients with advanced malignancies: a phase i and pharmacokinetic study

✍ Scribed by S. Faivre; C. Delbaldo; P. Pautier; V. Boige; S. Henriet; F. Namouni; C. Eyndels; R. Peck; J. Armand; E. Raymond

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety of repeated administrations of ix

✍ Sandrine Faivre; Catherine Delbaldo; Valérie Boige; Patricia Pautier; Jean-Charl 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 186 KB

409 AP23573, an mTOR inhibitor, administ

✍ M. Mita; E. Rowinsky; A. Mita; S. Syed; Q. Chu; M. Goldston; H. Knowles; V. Rive 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 149 KB

Phase I dose-escalating study of ES-285

✍ C. Massard, R. Salazar, J. P. Armand, M. Majem, E. Deutsch, M. García, A. Oaknin 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 591 KB

Phase I clinical and pharmacokinetic stu

✍ Brigitte Tranchand; Gilles Catimel; Catherine Lucas; Marlis Sarkany; Gérard Bast 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 222 KB

427 POSTER Pharmacokinetics (PK) of EZN-

✍ A. Patnaik; M. Goldston; C. Takimoto; A. Tolcher; K. Papadopoulos; T. Bekaii-Saa 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 87 KB

Phase I and pharmacokinetic study of ora

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 144 KB